trial

A Study of SEP-380135 in Adults With Schizophrenia or Major Depressive Episode

NCTId NCT07549581
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 1 · Completed
Enrollment 43 (actual)
Sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc.
Primary completion 2025-09-12
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 1
Status
Completed
Enrollment
43 (actual)
Study type
Interventional
Allocation
Randomized
Model
Sequential
Masking
Double
Start
2024-11-07
Primary completion
2025-09-12
Eligibility
ALL · 18 Years · 55 Years

Interventions & indications

Drugs
SEP-380135

Sponsors

Otsuka Pharmaceutical Development & Commercialization, Inc.Lead Sponsor

Sites

1 total
Los Alamitos, United States

Facts & assertions

4 sourced
Enrollment
43
Phase
PHASE1
Primary Completion Date
2025-09-12
Status
COMPLETED
relationships
The graph out of here
drug
SEP-380135
drug
lead_sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
company
indication
Bipolar Disorder
indication
Major Depressive Disorder (MDD)
indication
Depressive Disorder, Major
indication